AsiaNet 87821

MANCHESTER, England and HYDERABAD, India, Jan. 28, 2021/PRNewswire=KYODO JBN/--

    Sai Life Sciences, one of India's fastest growing Contract Research,

Development & Manufacturing Organizations (

https://www.sailife.com/?utm_source=pr&utm_medium=web&utm_campaign=double-headcount-capabilities-expansion-uk)

(CRDMOs), today announced plans to double its headcount and expand its suite of

technical capabilities at its Manchester site, a centre of excellence for API

process and analytical development serving an expanding list of global clients.

    Making the announcement, Krishna Kanumuri, CEO & Managing Director, Sai

Life Sciences, said, "We are truly heartened by our customers' response to our

Manchester site. The site serves as a vital bridge to our pilot and

manufacturing facilities in India, enabling seamless integration with the rest

of our service offerings across the USA and India, spanning the drug discovery,

development, and commercialisation continuum. This expansion will further

enhance our ability to add value to the NCE pipelines of our customers."

    The Sai Life Sciences' Manchester site (

http://www.sailife.com/alderley-park-manchester-uk/?utm_source=pr&utm_medium=web&utm_campaign=double-headcount-capabilities-expansion-uk)

became fully operational in August 2020, onboarded 24 members of staff and has

since delivered multiple projects involving complex chemistry. With a growing

interest from customers across the UK, Europe and US, the present expansion

involves an increase in capacity from 20 to 75 fume cupboards and an increase

in headcount from 24 to 50+ scientists. A further expansion will see the

addition of a GMP Kilo Lab later in 2021. The company has recently commenced

recruitment for multiple positions

(https://www.sailife.com/current-openings-in-manchester/?utm_source=pr&utm_mediu

m=web&utm_campaign=double-headcount-capabilities-expansion-uk) across API

process and analytical research & development, particle sciences and

engineering.

    Located in the heart of the Alderley Park life-sciences ecosystem, Sai Life

Sciences' Manchester site creates opportunities for UK and EU based pharma

companies and biotechs to have easier face-to-face collaboration with its

scientists, and to provide easier collaboration with US based clients due to

reduced time zone differences. The centre of excellence is well-positioned to

provide world-class development, scale-up and technology transfer to the Indian

sites as and when required. This new expansion will also add capability in

several key areas including process analytical technology (PAT),

crystallisation development and physical properties analysis.

    Sai Life Sciences is currently amid an organization-wide transformation. It

is investing US$150 million during 2019-23, as part of the Sai Nxt (

https://www.sailife.com/sai-life-sciences-announces-sai-nxt-an-initiative-to-transform-the-organization-into-a-new-generation-cdmo/?utm_source=pr&utm_medium=web&utm_campaign=double-headcount-capabilities-expansion-uk)

initiative, across three core areas – people & culture, processes & automation,

infrastructure & scientific capabilities.

    About Sai Life Sciences

    Sai Life Sciences is a full-service CRO/ CDMO (

https://www.sailife.com/?utm_source=pr&utm_medium=web&utm_campaign=double-headcount-capabilities-expansion-uk)

driven by a vision to support the launch of 25 new medicines by 2025. It works

with innovator pharma and biotech companies globally, accelerating the

discovery, development, and manufacture of complex small molecules. As a

pure-play CRO-CDMO, Sai Life Sciences has served diverse NCE development

programs, consistently delivering value based on its quality and

responsiveness. Today, it works with 7 of the top 10 large pharma companies, as

well as several small and mid-sized pharma & biotech companies. Sai Life

Sciences is privately held and backed by global investors, TPG Capital and HBM

Healthcare Investments. www.sailife.com

    Photo:

https://mma.prnewswire.com/media/1428651/Sai_Life_Sciences_UK_Expansion.jpg

    Logo: https://mma.prnewswire.com/media/1044186/Sai_Life_Sciences_Logo.jpg

    Source: Sai Life Sciences